Abstract
Lung cancer is the leading cause of cancer related deaths accounting for more deaths than breast, colon and prostate cancers combined. The Rb-p16 regulatory pathway plays an essential role in tumor suppression in the lung epithelium. This is evidenced by the nearly universal alterations in Rbp16 pathway components in lung cancer, and the increased incidence of pulmonary carcinomas in persons with germline Rb mutations. Interestingly, p16 loss and Rb mutations preferentially occur in phenotypically distinct lung cancer subtypes. Analysis of human tumors has identified progressive preneoplastic lesions that accumulate molecular alterations in an orderly sequence. Epigenetic p16 gene modifications represent an early event in lung cancer progression. This review summarizes the human studies that demonstrate a critical role for the Rb-p16 tumor suppressor pathway in lung carcinogenesis, and discusses how these findings in combination with genetically engineered mouse models have significantly contributed to our understanding of lung cancer pathogenesis.
Keywords: Lung cancer, retinoblastoma, Rb, p16, cyclin D, p130
Current Molecular Medicine
Title: Retinoblastoma Regulatory Pathway in Lung Cancer
Volume: 6 Issue: 7
Author(s): Kathryn A. Wikenheiser-Brokamp
Affiliation:
Keywords: Lung cancer, retinoblastoma, Rb, p16, cyclin D, p130
Abstract: Lung cancer is the leading cause of cancer related deaths accounting for more deaths than breast, colon and prostate cancers combined. The Rb-p16 regulatory pathway plays an essential role in tumor suppression in the lung epithelium. This is evidenced by the nearly universal alterations in Rbp16 pathway components in lung cancer, and the increased incidence of pulmonary carcinomas in persons with germline Rb mutations. Interestingly, p16 loss and Rb mutations preferentially occur in phenotypically distinct lung cancer subtypes. Analysis of human tumors has identified progressive preneoplastic lesions that accumulate molecular alterations in an orderly sequence. Epigenetic p16 gene modifications represent an early event in lung cancer progression. This review summarizes the human studies that demonstrate a critical role for the Rb-p16 tumor suppressor pathway in lung carcinogenesis, and discusses how these findings in combination with genetically engineered mouse models have significantly contributed to our understanding of lung cancer pathogenesis.
Export Options
About this article
Cite this article as:
Wikenheiser-Brokamp A. Kathryn, Retinoblastoma Regulatory Pathway in Lung Cancer, Current Molecular Medicine 2006; 6 (7) . https://dx.doi.org/10.2174/1566524010606070783
DOI https://dx.doi.org/10.2174/1566524010606070783 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets Advanced Development Strategies for Biopharmaceutical Cell Culture Processes
Current Pharmaceutical Biotechnology Chemical & RNAi Screening at MSKCC: A Collaborative Platform to Discover & Repurpose Drugs to Fight Disease
Combinatorial Chemistry & High Throughput Screening Putative Mechanisms of Viral Transmission and Molecular Dysregulation of Mammary Epithelial Cells by Human Papillomavirus: Implications for Breast Cancer
Current Molecular Medicine Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Drug Repurposing for Retinoblastoma: Recent Advances
Current Topics in Medicinal Chemistry Ras-Induced Senescence and its Physiological Relevance in Cancer
Current Cancer Drug Targets Episomal Vectors for Gene Therapy
Current Gene Therapy New Strategies and Patent Therapeutics in EBV-Associated Diseases
Mini-Reviews in Medicinal Chemistry Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Current Medicinal Chemistry Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Mouse Models of Primary Sjogren’s Syndrome
Current Pharmaceutical Design Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design Subject Index To Volume 3
Current Neurovascular Research Measurement of Cdk4 Kinase Activity Using an Affinity Peptide-Tagging Technology
Combinatorial Chemistry & High Throughput Screening Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design